$5.13
▼ -0.8% Today
as of Jul 22, 16:50 ET
Last 30 days
Recent Press Releases & News
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics (IOVA) Updates its Corporate Presentation, Here’s What’s Important to Note
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Overview
52-week range
$1.66
$5.63
87% of range
Avg surprise (last 3)
-19.3%
Avg reaction (last 2)
-6.0%
50% positive
Latest IV / EM
131%
EM ±7.7% · $5 · Jul 24
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.19 | $-0.19 | 0.0% | +47.2% | -13.2% | earnings |
| Thu Aug 7, 2025 | Jun/2025 | $-0.33 | $-0.29 | -13.8% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.36 | $-0.25 | -44.0% | — | +1.3% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.28 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.34 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.42 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.46 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.47 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.17 | -$0.33 | +48.5% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $42M | — | $38M | $57M | $43M | — | $32M | $31M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-81M | — | $-95M | $-114M | $-121M | — | $-89M | $-102M |
| Net income | $-79M | — | $-91M | $-112M | $-116M | — | $-84M | $-97M |
| EPS (diluted) | $-0.19 | — | — | $-0.33 | $-0.36 | — | $-0.28 | $-0.34 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $197M | $163M | $158M | $132M | $172M | $116M | $164M | $229M |
| Inventory | $58M | $52M | $52M | $50M | $66M | $52M | $39M | $28M |
| Total current assets | $467M | $443M | $429M | $422M | $513M | $457M | $499M | $482M |
| Total assets | $926M | $913M | $905M | $907M | $967M | $910M | $991M | $964M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $204M | $215M | $203M | $209M | $199M | $200M | $218M | $196M |
| Total equity | $722M | $699M | $702M | $698M | $768M | $710M | $773M | $769M |